Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.05M Buy
10,514
+9,129
+659% +$1.89M 0.04% 248
2026
Q1
$311K Buy
1,385
+4
+0.3% +$997 0.01% 1066
2025
Q4
$333K Buy
1,381
+550
+66% +$141K 0.01% 1007
2025
Q3
$227K Sell
831
-634
-43% -$173K 0.01% 1209
2025
Q2
$378K Sell
1,465
-455
-24% -$109K 0.02% 792
2025
Q1
$430K Buy
+1,920
New +$448K 0.02% 762
2024
Q4
Sell
-2,961
Closed -$723K 3457
2024
Q3
$723K Sell
2,961
-4,060
-58% -$907K ﹤0.01% 2469
2024
Q2
$1.34M Buy
+7,021
New +$1.42M ﹤0.01% 1806
2024
Q1
Sell
-22,324
Closed -$4.09M 4329
2023
Q4
$3.84M Buy
+22,324
New +$3.43M 0.01% 1188

Other funds holding RMD

GTS Securities's RMD Position: Q2 2026 in Review

GTS Securities increased its ResMed (RMD) stake by 659% in Q2 2026, buying an estimated $1.89M and bringing the position to 10,514 shares worth $2.05M. The position accounts for 0.04% of the portfolio, ranked #248.

GTS Securities first reported a position in RMD in Q4 2023 and has held it in 9 quarters since. The position peaked at $3.84M in Q4 2023. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • GTS Securities held 10,514 shares of ResMed worth $2.05M as of Q2 2026.
  • GTS Securities bought 9,129 ResMed shares in Q2 2026, an estimated $1.89M.
  • ResMed made up 0.04% of GTS Securities's portfolio in Q2 2026, its #248 holding.
  • GTS Securities first reported a position in ResMed in Q4 2023 and has held it in 9 quarters since.
  • GTS Securities's ResMed position peaked at $3.84M in Q4 2023.
  • 889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.